GE HealthCare reported its third quarter 2024 financial results, showing a mixed performance. The company beat Wall Street estimates on earnings per share (EPS), reporting a Non-GAAP EPS of $1.14, which exceeded expectations by $0.09. However, it missed revenue expectations, reporting $4.86 billion, which was $10 million short of forecasts. Despite the revenue miss, the company's stock rose as U.S. medical device demand offset a slowdown in the Chinese market. GE HealthCare also raised its annual earnings guidance, although it noted that full-year organic revenue growth is now trending towards the lower end of the previously expected 1-2% range due to continued softness in the China market. The stock showed a pre-market change of +0.4%.